For a moment, South Korea’s startup ecosystem held its breath. With the fate of the “DoctorNow Prevention Bill,” the country stands at a divided crossroads over how to govern innovation itself. As Korea strives to lead Asia’s digital transformation, this reversal exposes a deeper struggle between regulatory caution and the pursuit of next-generation industries.

Korea’s New Telemedicine Framework Highlights a Divided Approach to Innovation

South Korea has formally legalized telemedicine through a long-awaited amendment to the Medical Service Act, but lawmakers stopped short of approving medicine delivery or pharmaceutical distribution via digital platforms.

The decision follows weeks of fierce debate surrounding the so-called “DoctorNow Prevention Bill,” which sought to ban telemedicine companies from operating drug wholesale businesses.

The bill was eventually withdrawn from the National Assembly’s plenary agenda on December 2 after growing public backlash and concerns that it mirrored the politically charged “TADA Ban Law” of 2020.

The outcome leaves Korea’s digital healthcare sector standing at a crossroads: recognized as legitimate under national law yet constrained by ongoing disputes over where innovation should end and regulation should begin.

From Controversy to Caution: Inside the Legislative Reversal of the ‘DoctorNow Prevention Bill’

The proposed Pharmaceutical Affairs Act amendment, led by Democratic Party lawmaker Kim Yoon, aimed to prevent telemedicine platforms from running pharmaceutical distribution operations.

The move was widely viewed as targeting DoctorNow, Korea’s largest telemedicine startup, which had established a licensed drug wholesaler, Bejin Pharm, to address what patients called the “pharmacy ping-pong” problem—having to visit multiple pharmacies to find prescribed medicines.

DoctorNow’s integrated model allowed users to identify pharmacies with available stock and reduced prescription delays. However, critics, including the Korean Pharmaceutical Association, accused the company of leveraging its platform power to favor certain pharmacies and promote products linked to specific investors.

Allegations of indirect rebates then surfaced, though no evidence was formally established.

Still, despite passing through preliminary committees, the amendment was eventually excluded from the final plenary vote. Lawmakers cited the need for additional review, following widespread criticism from the startup sector and public complaints about disrupted patient access.

Despite the public focus on patient access and consumer convenience, observers noted oppositions that stem from structural incentives within Korea’s healthcare market.

Doctors gain little financially from telemedicine since they receive only the standard prescription fee, while in-person visits that include tests or procedures remain more profitable. Pharmacists, particularly those operating near major hospitals, fear losing their advantage if medicine delivery becomes commonplace.

As a result, both doctors and pharmacists have resisted digital health platforms to protect their existing market positions.

Diverging Voices on ‘DoctorNow Prevention Bill’ Across Stakeholders

The Ministry of Health and Welfare defended the bill as a safeguard against conflicts of interest in drug distribution, arguing that it was not a “second TADA ban” but a clarification of fair market boundaries.

Minister Jung Eun-kyung stated during the National Assembly’s Health and Welfare Committee session on November 26,

“The bill does not prohibit telemedicine itself but aims to address problems that arise when a platform operator also serves as a drug wholesaler. The same restriction already applies to hospitals and pharmacies and extending it to platforms is a matter of consistency.”

Industry organizations, however, sharply disagreed. The Korea Venture Business Association (KOVA) called the proposal “a symbolic regression” in its official statement on November 30, saying:

“The so-called ‘DoctorNow Prevention Bill’ lays bare the reality of Korea’s venture ecosystem after 30 years. Certain vested-interest groups have dominated the debate, while the Ministry of Health and Welfare has overturned its own earlier judgment to label an entire industry as problematic.
It is intolerable that innovative companies are repeatedly portrayed as villains.”

The Korea Startup Forum (KOSPO) echoed the criticism, describing the move as “a repeat of the Tada pattern, where innovative services are penalized for outpacing outdated frameworks.”

The forum’s statement added,

“Issues such as rebates, inducement, and unfair advantage are already covered under the Pharmaceutical Affairs Act and the Fair Trade Act. Creating another layer of restriction without evidence of actual harm only deepens uncertainty for startups operating under existing approvals.”

Beyond the ‘DoctorNow Prevention Bill’: A Broader Pattern of Policy Inconsistency

While the “DoctorNow Prevention Bill” failed to advance, the broader debate reflects a recurring struggle within Korea’s innovation ecosystem.

Over the past five years, sectors such as mobility, legaltech, and fintech have all faced similar pushbacks from traditional associations. Startups like LawTalk, Samjeomsam (3o3), and Gangnam Unni have each encountered restrictive amendments rooted in professional guild resistance rather than consumer harm.

Observers within the global venture community note that these cycles of abrupt regulatory intervention threaten Korea’s claim to being a stable innovation hub. The inconsistency between national rhetoric promoting the “Third Venture Boom” and the reactive legislative pattern risks weakening long-term investor confidence.

The controversy also underscores a missing perspective: the patient. While policymakers and associations debate governance boundaries, patients have voiced frustration over difficulties in accessing prescribed medication under current restrictions.

Online forums show recurring complaints about searching multiple pharmacies or being unable to obtain prescribed drugs after hours.

Telemedicine Legalization: Progress Shadowed by Delay

Although the DoctorNow Prevention Bill was shelved, the concurrent passage of Korea’s telemedicine legalization bill marked a significant milestone.

The new framework authorizes remote medical consultations nationwide for follow-up care, while initial consultations remain limited to patients within their residential regions.

However, the law maintains the prohibition on direct medicine delivery, leaving unresolved tensions between safety oversight and convenience.

Telemedicine associations welcomed the decision as “a long-overdue step forward,” but warned that the absence of medicine delivery rights undermines the sector’s practical viability.

Industry representatives have indicated they will continue lobbying for an updated pharmaceutical framework that enables safe, trackable prescription delivery under regulated conditions.

What the DoctorNow Saga Reveals About Korea’s Innovation Trajectory

Ultimately, this episode of DoctorNow Prevention Bill highlights Korea’s deeper dilemma in balancing governance credibility with the need to sustain innovation momentum. After all, while the bill’s collapse offers temporary relief to startups, the underlying conflict remains unresolved.

The outcome of this saga signals that Korea’s policy architecture still leans toward risk avoidance rather than innovation enablement—a perception that could influence how foreign investors assess its startup landscape.

As the government pushes its “Third Venture Boom” agenda, the DoctorNow saga will remain a litmus test for whether Seoul can build a regulatory culture that rewards experimentation while maintaining fairness and safety.

The next legislative cycle, which will revisit both telemedicine and drug distribution frameworks, may ultimately determine whether Korea’s digital-health economy becomes a pillar of its global competitiveness or another casualty of regulatory hesitation.

– Stay Ahead in Korea’s Startup Scene –
Get real-time insights, funding updates, and policy shifts shaping Korea’s innovation ecosystem.
➡️ Follow KoreaTechDesk on LinkedIn, X (Twitter), Threads, Bluesky, Telegram, Facebook, and WhatsApp Channel.